ABOS
Acumen Pharmaceuticals, Inc. - Common Stock$2.27Price Chart
Quant Score History
0 weakest · 5 strongestTechnical Indicators
RSI (14)
59.0
Dividends & Splits
Ex-Dividend
No dividend history.
Split
No splits on record.
Company Overview
Statement fields are the latest reported fiscal year (FY2025 FY), not a rolling TTM.
Market Cap
137.51M
P/E
-1.14
Fwd P/E
-1.40
P/B
0.76
P/S
—
EV/Rev
—
Div Yield
—
Div/Share
—
Revenue (FY)
—
Net Income (FY)
-121.33M
EPS (FY)
-2.00
Profit Margin
—
ROE
-66.74%
ROA
-104.59%
52W High
3.60
52W Low
1.50
50D MA
2.45
200D MA
2.54
Shares Out
60.58M
Analyst Target
7.60
Factor Grades
BuyValue
Growth
Profit.
Momentum
EPS Rev.
Quant Score: 3.2 / 5
Model score computed from reported data. Not a recommendation.
Risk & Return
Ann. Return
17.03%
Volatility
81.75%
Sharpe
0.19
Beta
—
Alpha
—
Max Drawdown
72.48%
VaR (95%)
7.44%
Sortino
0.30
Upcoming Earnings
News
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Opens in a new tab ↗Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Opens in a new tab ↗4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Opens in a new tab ↗Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Opens in a new tab ↗Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Opens in a new tab ↗Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...
Opens in a new tab ↗Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Opens in a new tab ↗Acumen Pharmaceuticals Q2 Earnings Call Highlights
Opens in a new tab ↗Analysed Articles
20 scoredMean
+0.05
Bullish
1
Neutral
19
Bearish
0
Polarity of crawled news items tagged to this symbol.